Compare SEV & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEV | TTRX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | 46 | 2 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 107.2M |
| IPO Year | N/A | N/A |
| Metric | SEV | TTRX |
|---|---|---|
| Price | $2.14 | $5.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 228.4K | 52.4K |
| Earning Date | 05-16-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,757.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $2.57 |
| 52 Week High | $11.24 | $6.75 |
| Indicator | SEV | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.63 | 65.47 |
| Support Level | $1.29 | $3.92 |
| Resistance Level | $3.26 | N/A |
| Average True Range (ATR) | 0.17 | 0.55 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 0.00 | 63.93 |
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.